Department of Hematology, Sir Ganga Ram Hospital, New Delhi, India.
Department of Laboratory Oncology, B.R.A.I.R.C.H., AIIMS, New Delhi, India.
Leuk Res. 2021 Aug;107:106651. doi: 10.1016/j.leukres.2021.106651. Epub 2021 Jun 29.
Assessment of myelodysplasia (MDS) by flow cytometry (FCM) includes elaborate panels, and interpretation is observer-dependent. This study evaluates single tube 10-color FCM in a test cohort of clinically suspected MDS patients.
We analyzed fifty-six bone marrow (BM) samples from clinically suspected MDS patients in a morphology-blinded manner along with controls using a 10-color single tube flow cytometry. We analyzed the reproducibility of Ogata score and modified FCM scores, additionally incorporating the proportion of CD15, CD11b, CD56, and CD38MFI on CD34+CD19-cluster for each patient. Patients were grouped as proven-MDS, suspected-MDS, and non-MDS groups based on morphology and cytogenetics. Optimized multi-axial radar-plots were also used to analyze maturation patterns in the granulocytic, monocytic, and blast progenitor compartments of proven-MDS cases and controls.
Flow cytometric abnormalities ≥3 were present in proven-MDS (n = 23) with a sensitivity and specificity of 78 % and 94 %, respectively, as per Ogata score. The addition of CD38 MFI to the score yielded sensitivity and specificity of 82 % and 88 %, respectively. Additional analysis of aberrant expression of CD15, CD11b, and CD56 increased the diagnostic power of the FCM score. A qualitative analysis of data also showed differences in maturation patterns in proven-MDS compared to the control group.
Single tube 10-color FCM scoring, including Ogata score, modified-FCM scores, and radar plots pattern analysis, showed significant abnormalities in proven-MDS cases in this pilot study. Large databases, including FCM-scoring and pattern-based analysis for normal BM maturation, could be further validated and standardized for screening MDS.
流式细胞术(FCM)评估骨髓增生异常综合征(MDS)包括精心设计的检测面板,其解读依赖于观察者。本研究通过对一组临床疑似 MDS 患者的检测,评估了单管十色 FCM。
我们以形态学盲法对 56 例临床疑似 MDS 患者的骨髓(BM)样本进行了分析,同时对对照组也进行了分析,使用的是单管十色流式细胞术。我们分析了 Ogata 评分和改良 FCM 评分的重现性,此外还纳入了每位患者 CD34+CD19-群中 CD15、CD11b、CD56 和 CD38MFI 的比例。根据形态学和细胞遗传学,患者被分为确诊 MDS 组、疑似 MDS 组和非 MDS 组。我们还使用优化的多轴雷达图分析了确诊 MDS 病例和对照组中粒细胞、单核细胞和原始细胞祖细胞区的成熟模式。
根据 Ogata 评分,在确诊 MDS(n=23)患者中存在≥3 项流式细胞术异常,其敏感性和特异性分别为 78%和 94%。将 CD38MFI 加入评分后,敏感性和特异性分别为 82%和 88%。对 CD15、CD11b 和 CD56 的异常表达进行额外分析提高了 FCM 评分的诊断能力。数据分析的定性分析还表明,与对照组相比,确诊 MDS 患者的成熟模式存在差异。
在这项初步研究中,单管十色 FCM 评分,包括 Ogata 评分、改良 FCM 评分和雷达图模式分析,在确诊 MDS 病例中显示出明显异常。进一步验证和标准化包括 FCM 评分和基于模式的正常 BM 成熟度分析的大型数据库,可用于 MDS 的筛查。